Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zydus Cadila Readies Injectables Push

Building Pipeline Amid Tepid US Growth Outlook, As Remdesivir Launches In India

Executive Summary

Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and the firm has just launched its Remdac version of remdesivir.

You may also be interested in...



India’s Saptagir Partners With Jubilant On Remdesivir

India’s Saptagir Laboratories has struck a deal with Jubilant Pharma to manufacture the ingredient for COVID-19 emergency treatment remdesivir. Meanwhile, following in the footsteps of Cipla, Hetero, Mylan and Zydus, Dr Reddy’s has launched its version of remdesivir for the Indian market under a licensing deal with Gilead.

Novavax-Serum Institute Seal Win-Win Deal For COVID-19 Vaccine

Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in selected regions, in another endorsement of the Indian group's capabilities. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India until the deal ends and non-exclusive rights for developing countries to the end of the pandemic, with the US firm getting half of net revenue.

Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel